IEDDA Clearing Trap Columns for Off-Site Toxicity Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pretargeting approaches face challenges in efficiently removing circulating targeting vectors from the bloodstream, leading to off-site toxicity and reduced therapeutic index due to prolonged circulation through non-target tissues, and existing extracorporeal clearing methods are not adaptable across different interaction pairs.
Innovation Solution
An extracorporeal clearing trap column utilizing inverse electron demand Diels-Alder (IEDDA) cycloaddition chemistry is employed, featuring a biocompatible solid support with complementary IEDDA-reactive moieties to selectively trap targeting vectors, allowing for efficient removal of circulating vectors and enhancing the delivery of effector probes to target sites.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If targeting vectors are used in pretargeted therapy, then therapeutic and diagnostic efficacy is improved, but off-site toxicity increases due to prolonged circulation through non-target tissues
Solution Approach 1:
The patent extracts circulating targeting vectors from the bloodstream using an extracorporeal clearing trap column. The column contains IEDDA-reactive moieties that selectively bind and remove targeting vectors from blood, separating them from the circulatory system before they can cause off-site toxicity. This extraction approach directly addresses the harmful effect while preserving the therapeutic benefit of the targeting vectors at the tumor site.
Solution Approach 2:
The patent introduces an intermediary clearing trap column between the administration of targeting vectors and their potential harmful effects. This intermediary device uses IEDDA chemistry as a mediator to selectively interact with and remove circulating targeting vectors, preventing them from reaching non-target tissues while allowing the main therapeutic effect to proceed.
2Productivity
If targeting vectors circulate in the bloodstream, then delivery to target site is achieved, but clearance from non-target tissues is delayed
Solution Approach 1:
The patent applies preliminary action by pre-positioning IEDDA-reactive moieties in the clearing trap column before circulating targeting vectors arrive. When targeting vectors enter the column, they are immediately captured by the pre-positioned reactive moieties, accelerating their removal from circulation. This preliminary setup enables rapid clearance without delaying target site delivery.
3Object-affected harmful factors
If extracorporeal clearing is implemented, then off-site toxicity is reduced, but device complexity increases
Solution Approach 1:
The patent replaces complex mechanical clearance systems with a chemical solution. Instead of using mechanical filters or physical separation methods, the clearing trap column uses IEDDA chemical reactions to selectively bind and remove targeting vectors. This substitution simplifies the device architecture while maintaining effective clearance functionality.
4Productivity
If circulating targeting vectors are present, then therapeutic agent delivery is enabled, but tumor-to-background ratio is reduced
Solution Approach 1:
The patent extracts circulating targeting vectors from the bloodstream using the clearing trap column, removing the source of background signal. By selectively removing unbound vectors before they can distribute to non-target tissues, the method enhances the tumor-to-background ratio while preserving delivered agents at the tumor site through the same IEDDA-based selective binding mechanism.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively reduces off-site toxicity and improves the tumor-to-background ratio by rapidly clearing targeting vectors from the bloodstream, thereby increasing the efficiency and safety of pretargeted therapy and diagnostics.
Implementation Method 1
The means for extracorporeal removal of the targeting vectors is based on binding agents with inverse electron demand Diels-Alder (IEDDA) cycloaddition reactivity
Data Source
Figure 1
Figure 2A~2B
Figure 3
AI summary
The present invention provides extracorporeal removal of targeting vectors applied in pretargeted therapy and diagnostics in animals and humans. The method and the means for extracorporeal removal of the targeting vectors is based on binding agents with inverse electron demand Diels-Alder (IEDDA) cycloaddition reactivity. The targeting vector comprises a therapeutic agent, a diagnostic agent or a theranostic agent and a chemical entity with IEDDA reactivity whereas the extracorporeal means comprises a column with a biocompatible solid support to which a chemical entity with complementary IEDDA reactivity is attached.